Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
_↗ investor.lilly.com
News Image

Eli Lilly and Company is set to acquire Verve Therapeutics for an initial $1.0 billion in cash, with potential additional payments up to $3.00 per share via a Contingent Value Right (CVR) tied to the advancement of Verve's lead program, VERVE-102. This acquisition represents a strategic move for Lilly to bolster its pipeline of genetic medicines aimed at cardiovascular disease, specifically focusing on one-time gene editing treatments that could revolutionize chronic care. Verve's VERVE-102, a gene-editing therapy targeting PCSK9 to reduce cholesterol, is currently in a Phase 1b clinical trial for conditions like heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD), and has received Fast Track designation from the FDA. Lilly's acquisition, expected to close in Q3 2025, underscores its commitment to developing innovative solutions for significant unmet medical needs in cardiovascular health, with the goal of providing lifelong benefits through a single treatment.

Log In
Sign Up